Controlled studies of IVIg in multiple sclerosis
| Fazekas et al 7 | Achiron et al 9 | Sørensen et al 8 | |
|---|---|---|---|
| Sig, significant result; NS, not significant. | |||
| Design | Parallel | Parallel | Cross over |
| Patients included | 148 | 40 | 26 |
| Primary outcome | EDSS (sig) | Yearly exacerbation rate (sig), exacerbation free time (sig), time to first relapse (sig) | MRI (Gd+ lesions) (sig) |
| Secondary outcome | Number of relapses (sig), time between relypses (sig), time to first relapse (NS), severity of relapses (NS) | EDSS (trend, NS), severity of relapse (NS), MRI (T1, T2, spin echo) (NS) | MRI (T2) (NS), relapse free patients (sig), number of relapses (NS), multimodal evoked potentials (NS), EDSS (NS), NRS (NS) |
| Dosage | 0.15–0.2 g/kg monthly for 2 years | 2 g/kg loading, then 0.4 g/kg every other month for 2 years | 2 g/kg monthly for 6 months, then cross over |